Abstract
<p>In the present study, the effect of ursolic acid benzaldehyde chalcone (UABC) on ovarian carcinoma cells was studied. The results revealed that ovarian carcinoma cells on UABC treatment increased Sub-G1 cell population, increased rate of cell apoptosis and morphological changes in mitochondrial membrane. In OVCAR 432 cells treatment with UABC increased the Sub-G1 cell population to 72.3% and growth inhibition rate of &gt;72%. Treatment with 20 µM of UABC for 48 hours, led to an induction of apoptosis in 67.2% and induced morphological changes in OVCAR 432 cells. The Western blot results showed high concentration of cytochrome c in the cell cytosol after 48 hours of UABC treatment. Treatment of RMS-13 cells with UABC resulted in inhibition of GLI1, GLI2, PTCH1, and IGF2 genes. In addition, we found a significant reduction in hedgehog activity of RMS-13 cells after UABC treatment by means of a hedgehog-responsive reporter assay. Therefore, UABC can be a promising agent for the treatment of ovarian carcinoma.</p>
Highlights
Ovarian carcinoma because of late stage detection is the most lethal gynecological malignancy
The results of the analysis showed that ursolic acid benzaldehyde chalcone (UABC) induces a higher rate of apoptosis compared to untreated control cells (Figure 3)
On the other hand cytochrome c concentration in the mitochondrial fraction inversely decreased (Figure 4B). These results clearly indicate that UABC-induced apoptosis in OVCAR 432 cells is mediated by the intrinsic apoptotic pathway
Summary
Ovarian carcinoma because of late stage detection is the most lethal gynecological malignancy. It is usually diagnosed after tumor cells are widely metastasized within the peritoneal cavity. All the treatments for ovarian carcinoma at present are inefficient. New generations of oral fluoropyrimidine such as S-1, which inhibit the degradation of 5-FU and capecitabine have been developed and put into use in the treatment of several solid tumors (Schoffski, 2004). You must attribute the work in the manner specified by the author or licensor. In the present study we first time report the effect of ursolic acid chalcone (Figure 1) treatment of ovarian carcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
